S. Li

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin et al. · British Journal of Dermatology · 2017 · 339 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Alexa B. Kimball, Kim Papp, Yasmine Wasfi et al. · Journal of the European Academy of Dermatology and Venereology · 2012 · 211 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

Tsen‐Fang Tsai, Vincent Ho, Michael Song et al. · British Journal of Dermatology · 2012 · 94 citations

Public Health, Immunology, Pharmacotherapy +17

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to &lt; 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study

Sandra Philipp, Alan Menter, Arjen Nikkels et al. · British Journal of Dermatology · 2020 · 80 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <scp>VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Kristian Reich, Kim Papp, April W. Armstrong et al. · British Journal of Dermatology · 2018 · 69 citations

Medicine, Pharmacology, Pharmacotherapy +13